FIG 6.

Combination therapy with IL-12 and linezolid improves survival following MRSA pneumonia. WT and IFN-γ^−/− mice were challenged i.n. with 5 × 10⁸ CFU of MRSA and were then treated i.n. 4 and 24 h later with either PBS vehicle, IL-12 alone, linezolid alone, or a combination of IL-12 and linezolid. Survival of infected mice was monitored every 12 h for 7 days. Each group contained 7 to 10 mice, and the results of two independent experiments were pooled. *, P < 0.05 as determined by a log rank test.